XTRA:MRKPharmaceuticals
Is Merck KGaA (XTRA:MRK) Undervalued On Raised 2026 Guidance?
Merck KGaA (XTRA:MRK) recently raised its 2026 guidance, now expecting group net sales of about €21b to €21.8b and EPS pre of €7.90 to €8.60, which has refocused attention on the stock.
See our latest analysis for Merck KGaA.
At a share price of €138.35, Merck KGaA has seen a 9.45% 90 day share price return and a 14.06% year to date share price return. The 1 year total shareholder return of 26.40% contrasts with declines over 3 and 5 years, pointing to renewed but still fragile momentum after...